1. Home
  2. BSX vs VRTX Comparison

BSX vs VRTX Comparison

Compare BSX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BSX
  • VRTX
  • Stock Information
  • Founded
  • BSX 1979
  • VRTX 1989
  • Country
  • BSX United States
  • VRTX United States
  • Employees
  • BSX N/A
  • VRTX N/A
  • Industry
  • BSX Medical/Dental Instruments
  • VRTX EDP Services
  • Sector
  • BSX Health Care
  • VRTX Technology
  • Exchange
  • BSX Nasdaq
  • VRTX Nasdaq
  • Market Cap
  • BSX 138.4B
  • VRTX 115.6B
  • IPO Year
  • BSX 1992
  • VRTX 1991
  • Fundamental
  • Price
  • BSX $105.15
  • VRTX $442.05
  • Analyst Decision
  • BSX Strong Buy
  • VRTX Buy
  • Analyst Count
  • BSX 22
  • VRTX 26
  • Target Price
  • BSX $111.64
  • VRTX $512.54
  • AVG Volume (30 Days)
  • BSX 6.7M
  • VRTX 2.2M
  • Earning Date
  • BSX 07-23-2025
  • VRTX 05-05-2025
  • Dividend Yield
  • BSX N/A
  • VRTX N/A
  • EPS Growth
  • BSX 15.23
  • VRTX N/A
  • EPS
  • BSX 1.37
  • VRTX N/A
  • Revenue
  • BSX $17,554,000,000.00
  • VRTX $11,099,700,000.00
  • Revenue This Year
  • BSX $17.56
  • VRTX $10.36
  • Revenue Next Year
  • BSX $10.75
  • VRTX $10.61
  • P/E Ratio
  • BSX $76.80
  • VRTX N/A
  • Revenue Growth
  • BSX 19.36
  • VRTX 8.98
  • 52 Week Low
  • BSX $71.88
  • VRTX $377.85
  • 52 Week High
  • BSX $107.17
  • VRTX $519.88
  • Technical
  • Relative Strength Index (RSI)
  • BSX 57.52
  • VRTX 43.63
  • Support Level
  • BSX $103.50
  • VRTX $427.43
  • Resistance Level
  • BSX $106.67
  • VRTX $451.64
  • Average True Range (ATR)
  • BSX 1.64
  • VRTX 10.29
  • MACD
  • BSX -0.21
  • VRTX 2.22
  • Stochastic Oscillator
  • BSX 63.63
  • VRTX 72.63

About BSX Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: